The pharmaceutical market is seeing growth in orphan drugs, with more treatments becoming available for rare diseases. Recent developments, including a provisional deal on critical medicines and new agents for orphan diseases, suggest progress in this area. The outlook for orphan drugs appears to be at a crossroads, with increased numbers and potentially tougher regulatory decisions ahead.